Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
NCT01987492 · Hoffmann-La Roche · PHASE2 · terminated · last registry update 2026-11-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.” | – | Registry record, Hoffmann-La Roche |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL13 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-16Results posted on the registry: Eli Lilly and Company, Placebo + Lebrikizumab (NCT06280716)
- 2026-10-14Phase 3 first posted: Almirall, S.A., Lebrikizumab + Lebrikizumab (NCT07873801)
- 2026-09-10Results posted on the registry: Hoffmann-La Roche, Lebrikizumab + Placebo (NCT02546700)
- 2026-08-05Results posted on the registry: LEO Pharma, Tralokinumab + Placebo (NCT05958407)
- 2026-07-17Results posted on the registry: Almirall, S.A., Lebrikizumab (NCT05990725)
- 2026-07-17Results posted on the registry: Hoffmann-La Roche, Lebrikizumab + Montelukast (NCT02104674)
- 2026-07-17Results posted on the registry: Hoffmann-La Roche, Lebrikizumab + Placebo (NCT01867125)
- 2026-06-30Results posted on the registry: Hoffmann-La Roche, Lebrikizumab + Placebo (NCT01875003)
- 2026-06-30Also stopped (terminated): Hoffmann-La Roche, Lebrikizumab + Placebo (NCT01875003)
- 2026-05-22Also stopped (terminated): Psoriasis Treatment Center of Central New Jersey, tralokinumab (NCT06773455)
- 2026-04-21Phase 3 first posted: Almirall, S.A., Lebrikizumab (NCT07542483)
- 2026-04-06Results posted on the registry: Celgene, CC-93538 (NCT04991935)
- 2026-02-06Also stopped (terminated): University of Zurich, Application of Tralokinumab (NCT05378698)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision